Durect

DURECT Corporation is a biopharmaceutical company focused on the research, development, and manufacturing of innovative medicines for pain management and chronic diseases. Founded in 1998 and headquartered in Cupertino, California, the company develops a range of investigational drug candidates, including DUR-928, an orally bioavailable small molecule aimed at regulating lipid homeostasis and inflammation, and POSIMIR, an injectable designed to provide extended pain relief. DURECT employs proprietary delivery technologies that enhance the clinical and commercial attributes of both small-molecule and biologic drugs, with products such as REMOXY and ELADUR in its late-stage development pipeline. Additionally, the company markets its ALZET product line—osmotic pumps used in experimental research—and LACTEL branded biodegradable polymers through a direct sales force in the United States and a network of distributors internationally. DURECT maintains strategic collaborations with various pharmaceutical entities and universities to further its research and development efforts across multiple global markets.